Investigators from the Royal Marsden Hospital, Surrey, England, evaluated the efficacy of carboplatin in esophageal carcinoma.
Carboplatin is frequently substituted for cisplatin in chemotherapy protocols due to greater tolerability.
However, in certain tumor groups, including esophageal carcinoma, carboplatin is considered to be less active.
A total of 45 patients, who had inoperable esophageal cancer, were retrieved from a gastrointestinal cancer database.
|1-year survival after carboplatin therapy was 51%.
|GI Cancer |
Each had received first line chemotherapy, which incorporated carboplatin because of a contraindication to the use of cisplatin.
Contraindications included auditory dysfunction, renal impairment, and cardiac failure.
Of the patients, 17 (38%) had an objective response.
The median overall survival was 13.3 months, with failure-free survival of 11.5 months.
The researchers found that the 1-year survival was 51%.
They also compared these results to those previously reported by the same group for patients treated with cisplatin-containing regimens. They found that response, and overall and failure-free survival rates were all similar.
Tim Price concluded on behalf of his colleagues, "The substitution of carboplatin for cisplatin does not appear to be deleterious in the palliative treatment of advanced esophageal carcinoma."